Antisense, RNA
Antisense, RNA Companies (4)
Antisense, RNA News
-
News A United Cause: strategic partnership between BioNTech and the Government of the UK announced
A multi-year collaboration between BioNTech and the Government of the United Kingdom will see the expansion of the company’s presence in the UK, focusing on areas like cancer immunotherapies and infectious disease vaccines. -
News Phase III trials of Pfizer’s mRNA-based influenza vaccine begin
Leveraging their current mRNA vaccine technology developed during the COVID-19 pandemic, Pfizer have announced the start of phase III trials for a potential mRNA-based influenza vaccine. -
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA.
Antisense, RNA Products (5)
-
Product Oligonucleotide Analytical Development Services
Analytical development services for oligonucleotides: For oligo-based drugs, our capabilities range from GLP bioanalysis to GLP/cGMP characterisation. We support product development, from quality control testing of amidite starting materials and early stage product characterization through to GMP batch r... -
Product Large Molecule Discovery & Development Services
We provide a wide range of discovery and development services for New Biological Entities (NBEs) from our state-of-the-art facility located in Hyderabad, India. At the core of NBE services is a talented team of scientists experienced in the design and delivery of a range of advanced therapeutic modalities ... -
Product Oligonucleotides
Sumitomo Chemical has unique manufacturing technology for long (more than 100-mer) oligonucleotides with purity of 90% -
Product mRNA Characterisation and Analysis
Characterization and analysis of mRNA supporting vaccine and therapeutic development, including assessing clinical translation efficiency and immunogenicity. At our GLP / GCP / GMP laboratories, scientists can test a mRNA drug substance or drug product to help you confidently assess batch to batch manufa... -
Product ATB-301
[TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib
1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients
2. Confirm the suppression of IL-2’s side effect in combinati...
Upcoming Events
-
CPHI Japan 2023
Tokyo Big Sight, Tokyo, Japan
19 - 21 April 2023 -
CPHI North America 2023
Pennsylvania Convention Center, Philadelphia
April, 25-27, 2023 -
CPHI & PMEC China 2023
Shanghai New International Expo Center
19 - 21 June 2023
Pharmaceutical Industry Webinars
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance